DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

This study tests a new drug called DCSZ11 in combination with standard cancer treatments (chemotherapy and/or immunotherapy) in people with advanced or metastatic solid tumours — cancers that have spread and are no longer responding well to standard therapies alone. **You may be eligible if...** - You are 18 years or older - You have histologically confirmed advanced or metastatic solid tumours - You still have standard guideline-approved treatment options available (chemotherapy and/or immunotherapy) - If you have head and neck cancer, your tumour must have a PD-L1 score (CPS) of 1 or higher **You may NOT be eligible if...** - You have lung cancer with driver mutations and are eligible for targeted therapy instead - You are not a candidate for the standard treatments that DCSZ11 would be combined with - You have certain serious health conditions that make combination treatment unsafe Talk to your doctor to see if this trial is right for you.